ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0205

Methotrexate Therapy Is Not Associated with an Increased Risk of Liver Fibrosis Assessed by the Fibrosis-4 Index

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0181

Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0077

Mimickers of Immunoglobulin G4-Related Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0036

Molecular Phenotyping of Late-Stage Knee Osteoarthritis Synovium Through Total RNA-Sequencing

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0151

More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0173

mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0342

Multimorbidity Clusters in Psoriatic Arthritis: A Population-Based Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0330

Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0374

Neo-epitopes of Type I Collagen Can Be Utilized as Translational Biomarkers for Skin and Joint Turnover in Patients with Psoriasis and Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0340

Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0064

Neutrophil Extracellular Traps Are Sufficient to Activate the Alternative Pathway of Complement

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0070

Neutrophils Transiting Through Megakaryocytes During Emperipolesis Exhibit Distinct Fates and Acquire the Capacity to Guide Other Neutrophils via MK Trails

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0063

Novel Repurposed Drugs Against Joint Inflammation Reveal Potential Use for Gout Treatment: An In Silico, In Vitro and Clinical Study

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0196

Objectively-Measured Obstructive Sleep Apnea Is Frequent Among Individuals with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0402

Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].